Employing Synthetic T-cell Biology to Target AML without On-Target/Off-Cancer Toxicity

M Paulina Velasquez; Stephen Gottschalk

doi:10.1158/2643-3230.BCD-21-0127

Employing Synthetic T-cell Biology to Target AML without On-Target/Off-Cancer Toxicity

Blood Cancer Discov. 2021 Nov;2(6):559-561. doi: 10.1158/2643-3230.BCD-21-0127. Epub 2021 Sep 20.

Authors

M Paulina Velasquez¹, Stephen Gottschalk²

Affiliations

¹ Department of Bone Marrow Transplant and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
² Department of Bone Marrow Transplant and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee. stephen.gottschalk@stjude.org.

Abstract

Ideal targets for chimeric antigen receptor T-cell therapy for acute myeloid leukemia (AML) remain elusive. In this issue of Blood Cancer Discovery, Richards and colleagues explore CD93 as a potential AML target antigen, and devise an approach to mitigate "on-target/off-cancer toxicity."See related article by Richards et al., p. 648.

Publication types

Comment